256 related articles for article (PubMed ID: 15300147)
41. Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.
Khaled D; Taylor J; Holzbeierlein J
Urol Clin North Am; 2020 Feb; 47(1):119-128. PubMed ID: 31757295
[TBL] [Abstract][Full Text] [Related]
42. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.
Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
Investig Clin Urol; 2020 Jul; 61(4):349-354. PubMed ID: 32665991
[No Abstract] [Full Text] [Related]
43. Bladder cancer: current optimal intravesical treatment.
Lamm DL; McGee WR; Hale K
Urol Nurs; 2005 Oct; 25(5):323-6, 331-2. PubMed ID: 16294610
[TBL] [Abstract][Full Text] [Related]
44. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2011 Jan; 185(1):67-71. PubMed ID: 21074202
[TBL] [Abstract][Full Text] [Related]
45. Intravesical Bacillus Calmette-Guerin for treating bladder cancer.
Boyd LA
Urol Nurs; 2003 Jun; 23(3):189-91, 199; quiz 192. PubMed ID: 12861735
[TBL] [Abstract][Full Text] [Related]
46. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
47. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
48. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.
Packiam VT; Johnson SC; Steinberg GD
Cancer; 2017 Feb; 123(3):390-400. PubMed ID: 28112819
[TBL] [Abstract][Full Text] [Related]
49. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
50. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
51. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
[TBL] [Abstract][Full Text] [Related]
52. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
[TBL] [Abstract][Full Text] [Related]
53. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
Ooi WL; Stockler M; Hayne D
Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
[No Abstract] [Full Text] [Related]
54. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
[TBL] [Abstract][Full Text] [Related]
55. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
56. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
[TBL] [Abstract][Full Text] [Related]
57. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
58. The current status of intravesical therapy for superficial bladder cancer.
Patard JJ; Rodriguez A; Lobel B
Curr Opin Urol; 2003 Sep; 13(5):357-62. PubMed ID: 12917511
[TBL] [Abstract][Full Text] [Related]
59. [Panuveitis following intravesical bacille Calmette-Guerin therapy].
Jacob M; Gambrelle J; Fleury J; Durieu I; Kodjikian L; Duquesne N; Grange JD
J Fr Ophtalmol; 2006 May; 29(5):552-5. PubMed ID: 16885830
[TBL] [Abstract][Full Text] [Related]
60. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]